We differentiate ourselves by providing our clients and partners with the confidence of a successful antibody discovery program targeting GPCRs.

This critical class of drug targets is implicated in multiple major diseases, and we deliver innovative solutions to unlock their therapeutic potential.

Our RedQueen platform designs breakthrough biologics against complex protein receptors by uniting the principles of evolutionary computation with physics-based modeling and cutting-edge AI.

Through digital directed evolution, we replicate the natural process by which the immune system develops new antibodies, uncovering solutions that conventional technologies cannot reach.

We apply the principles of evolution to explore the vast space of antibody variants.

Unlike conventional generative AI, which often fails to predict effective new antibodies, our approach delivers accurate and reliable insights into antibody–antigen interactions.